1.	A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13895, CP12-0919, I4T-IE-JVBF, 2010-019318-26, NCT01140347
2.	A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13852, I4T-MC-JVBA, 2010-021297-11, CP12-1027, CTRI/2011/08/001942, NCT01168973
3.	A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13894, I4T-IE-JVBE, CP12-0922, 2010-020426-18, NCT01170663
4.	A Study in Second Line Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13856, I4T-MC-JVBB, CP12-0920, 2010-021037-32, CTRI/2011/07/001900, NCT01183780
5.	A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13942, CP20-0801, I4Y-IE-JCDB, NCT01111604
6.	A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13916, 14T-IE-JVBL, CP12-0917, 2009-016784-11, NCT01160744
7.	Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13944, CP20-0903, I4Y-IE-JCDD, NCT01234402
8.	A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14057, I4T-MC-JVBT, NCT01246960
9.	Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13943, CP20-0902, I4Y-IE-JCDC, NCT01282463
10.	A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14392, 14T-IE-JVCD, CP12-1134, NCT01427933
11.	A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14432, I4T-IE-JVCA, CP12-1032, NCT01515306
12.	A Study of Ramucirumab and Docetaxel in Patients With Solid Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14434, CP12-0713, I4T-IE-JVCC, NCT01567163
13.	A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14433, CP12-1033, I4T-IE-JVCB, NCT01634555
14.	A Study in Participants With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14139, I4T-CR-JVBU, NCT01682135